DMAC vs LXEO
DMAC: A clinical-stage biopharmaceutical company developing DM199, a recombinant human kallikrein-1 protein, to treat acute ischemic stroke, preeclampsia, and fetal growth restriction. LXEO: Lexeo is a clinical-stage genetic medicine company developing gene therapies targeting the genetic root causes of rare cardiovascular diseases like Friedreich ataxia cardiomyopathy.
Side-by-side fundamentals
| Metric | DMAC | LXEO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.93 | $4.87 | |
| Market cap as of 2026-07-23 | $376M | $365M | |
| PEG as of 2026-07-23 | -1.09 | n/a | |
| Net margin as of 2026-07-23 | -1146.8% | -11991.8% | DMAC higher |
| Operating margin as of 2026-07-23 | -1352.2% | -12408.4% | DMAC higher |
| ROE as of 2026-07-23 | -77.1% | -47.5% | LXEO higher |
| ROA as of 2026-07-23 | -69.2% | -41.7% | LXEO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | DMAC lower |
| Beta as of 2026-07-23 | 0.97 | 1.40 | |
| 1-year return as of 2026-07-22 close | +55.9% | +17.7% | DMAC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.